Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-302 plus trastuzumab in HER2-positive breast cancer
NCT02213744Phase 3Terminated
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Dec 2016
- Modality
- Antibody Fragments, Targeted Liposomes, Antibody-Drug Conjugates (ADCs)
- Countries
- 9
01
Overview
A Phase 3 trial of gancotamab in HER2-positive breast cancer, sponsored by Merrimack Pharmaceuticals. Started Jul 2014; status: terminated.
02
Drugs
gancotamab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02213744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213744.